Elixirgen Therapeutics is a biotechnology company that specializes in the development of therapies for genetic diseases and vaccines.
Elixirgen Therapeutics has raised $7.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in November 2023.
Elixirgen Therapeutics's investors include UTEC - The University of Tokyo Edge Capital Partners.
Elixirgen Therapeutics is headquartered in Baltimore, United States.
Elixirgen Therapeutics is a biotechnology company that specializes in the development of therapies for genetic diseases and vaccines.
Elixirgen Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Elixirgen Therapeutics — Funding & Investors." VCBacked, November 9, 2023, https://www.vcbacked.co/company/elixirgen-therapeutics. Accessed July 19, 2026.
VCBacked. (2023). Elixirgen Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/elixirgen-therapeutics
{{cite web |title=Elixirgen Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/elixirgen-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated